MCID: ACT058
MIFTS: 54

Active Peptic Ulcer Disease

Categories: Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Active Peptic Ulcer Disease

MalaCards integrated aliases for Active Peptic Ulcer Disease:

Name: Active Peptic Ulcer Disease 11 14
Gi Bleeding 11 14
Gastrointestinal Hemorrhage 71
Active Peptic Ulcer 71

Classifications:



External Ids:

Disease Ontology 11 DOID:749
UMLS 71 C0017181 C1706705

Summaries for Active Peptic Ulcer Disease

MalaCards based summary: Active Peptic Ulcer Disease, also known as gi bleeding, is related to dieulafoy lesion and gastrointestinal stromal tumor, and has symptoms including nausea and vomiting, constipation and vomiting. An important gene associated with Active Peptic Ulcer Disease is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) and Angiogenesis (CST). The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and kidney, and related phenotypes are homeostasis/metabolism and normal

Related Diseases for Active Peptic Ulcer Disease

Diseases related to Active Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)
# Related Disease Score Top Affiliating Genes
1 dieulafoy lesion 30.9 F2 ATP4A ATP12A
2 gastrointestinal stromal tumor 30.4 SST KIT ANO1 ALB
3 arteriovenous malformation 30.4 VWF F3 F2 ALB ACVRL1
4 intestinal tuberculosis 30.3 CRP ALB
5 klippel-trenaunay-weber syndrome 30.2 SST F2 ACVRL1
6 esophagitis 30.2 PTGS2 HRH2 CYP2C19
7 endocarditis 30.1 F2 CRP ALB
8 leech infestation 30.1 F3 F2 CYGB
9 thrombophilia due to thrombin defect 30.1 VWF F3 F2
10 iron deficiency anemia 30.1 CYGB CRP ATP4A
11 splenic artery aneurysm 30.1 F2 ATP4A ATP12A ACVRL1
12 aortic aneurysm 30.1 F3 F2 CRP ALB
13 atrophic gastritis 30.1 SST PTGS2 ATP4A ATP12A
14 duodenal ulcer 30.1 SST HRH2 CYP2C19
15 angiodysplasia 30.1 VWF SST F3 F2 ATP4A ATP12A
16 hypersensitivity vasculitis 30.1 F2 CRP ALB
17 vascular cancer 30.0 VWF KIT ANO1
18 meckel diverticulum 30.0 SST KIT CRP ATP4A ATP12A ALB
19 cavernous hemangioma 30.0 VWF F3 F2 ALB
20 chronic intestinal vascular insufficiency 30.0 CRP ATP4A ATP12A ALB
21 anus disease 30.0 CRP ATP4A ATP12A ALB
22 uremia 30.0 VWF CRP ALB
23 vitamin k deficiency bleeding 29.9 F7 F3 F2
24 factor vii deficiency 29.9 F7 F3 F2
25 purpura 29.9 VWF F3 F2 CRP
26 ischemic colitis 29.9 F3 F2 CRP ATP4A ATP12A ALB
27 intussusception 29.8 KIT CRP ANO1 ALB
28 acquired von willebrand syndrome 29.8 VWF F7 F3 F2
29 aortic aneurysm, familial thoracic 1 29.8 VWF CRP ALB ACVRL1
30 alcohol use disorder 29.8 GPT F2 CRP ATP12A ALB
31 vascular disease 29.8 VWF PTGS2 F3 F2 CRP ALB
32 zollinger-ellison syndrome 29.8 SST HRH2 ATP4A ATP12A
33 cholecystitis 29.7 GPT F2 CRP ALB
34 behcet syndrome 29.7 VWF F3 F2 CRP ALB
35 liver cirrhosis 29.7 SST GPT F3 F2 ALB
36 neurofibromatosis, type i 29.7 SST KIT ANO1
37 diarrhea 29.6 VWF SST HRH2 GPT ALB
38 factor viii deficiency 29.6 VWF F7 F3 F2 ALB
39 hernia, hiatus 29.5 HRH2 CYP2C19 CRP ATP4A ATP12A ALB
40 obstructive jaundice 29.4 SST GPT F2 CRP ALB
41 acute myocardial infarction 29.4 VWF F7 F3 F2 CRP ALB
42 esophageal varix 29.4 SST GPT F3 F2 CRP ATP4A
43 inguinal hernia 29.3 KIT GPT F3 F2 CRP ALB
44 portal hypertension 29.3 SST PTGS1 GPT F2 ALB
45 hemorrhoid 29.3 GPT F3 F2 CRP ATP4A ATP12A
46 aspiration pneumonia 29.2 GPT F3 F2 CRP ATP4A ATP12A
47 intestinal obstruction 29.2 KIT GPT F2 CRP ATP4A ATP12A
48 gastroesophageal reflux 29.2 PTGS2 PTGS1 HRH2 CYP2C19 ATP4A ATP12A
49 gastritis 29.1 SST PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
50 gastric ulcer 29.1 SST PTGS2 PTGS1 HRH2 CYP2C19 ATP12A

Comorbidity relations with Active Peptic Ulcer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 144)


Acquired Thrombocytopenia Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcohol Use Disorder Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alzheimer Disease, Familial, 1 Anus Disease
Aortic Valve Disease 1 Ascending Colon Cancer
Atrophic Gastritis Bacteremia 2
Benign Essential Hypertension Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiogenic Shock Cecal Benign Neoplasm
Cerebral Atherosclerosis Cerebrovascular Disease
Cholestasis Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin Chylomicron Retention Disease
Colon Carcinoma in Situ Colorectal Cancer
Conjunctivitis Crohn's Disease
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Descending Colon Cancer Disseminated Intravascular Coagulation
Duodenitis Duodenum Cancer
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development Esophageal Cancer
Esophageal Candidiasis Esophageal Disease

Graphical network of the top 20 diseases related to Active Peptic Ulcer Disease:



Diseases related to Active Peptic Ulcer Disease

Symptoms & Phenotypes for Active Peptic Ulcer Disease

UMLS symptoms related to Active Peptic Ulcer Disease:


nausea and vomiting; constipation; vomiting; fatigue; fever; hemoptysis; abdominal pain; chest pain; headache; pruritus; syncope; diarrhea; edema; pain; nausea; chronic pain; sciatica; halitosis; dyspepsia; icterus; coughing; vertigo/dizziness; heartburn; gastrointestinal gas; symptoms; digestive system symptom; pelvic pain; blood in stool

GenomeRNAi Phenotypes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ACVRL1 ALB ANO1 ATP12A ATP4A CRP
2 no effect GR00402-S-2 10.18 ACVRL1 ALB ANO1 ATP12A ATP4A CRP

MGI Mouse Phenotypes related to Active Peptic Ulcer Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.09 ACVRL1 ALB ANO1 ATP12A ATP4A CRP
2 normal MP:0002873 10.02 ACVRL1 ALB F2 F3 F7 KIT
3 neoplasm MP:0002006 9.95 ALB ATP4A CYGB F3 KIT PTGS1
4 renal/urinary system MP:0005367 9.92 ACVRL1 ALB ANO1 ATP12A CYGB KIT
5 muscle MP:0005369 9.91 ACVRL1 ALB ANO1 CYGB F2 F3
6 digestive/alimentary MP:0005381 9.73 ACVRL1 ALB ANO1 ATP12A ATP4A F2
7 cardiovascular system MP:0005385 9.4 ACVRL1 ALB ANO1 CRP CYGB F2

Drugs & Therapeutics for Active Peptic Ulcer Disease

Drugs for Active Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
4
Prucalopride Approved Phase 4 179474-81-8 3052762
5
Famotidine Approved Phase 4 76824-35-6 3325 5702160
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
8
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
9
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
10
Nadolol Approved Phase 4 42200-33-9 39147
11
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
12
Ceftriaxone Approved Phase 4 73384-59-5 5479530
13
Isosorbide dinitrate Approved, Investigational Phase 4 87-33-2 3780 6883
14
Isosorbide Approved, Investigational Phase 4 652-67-5 99937 12597
15
Nitric Oxide Approved Phase 4 10102-43-9 145068
16
Prazosin Approved Phase 4 19216-56-9 4893
17
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
18
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
19
Reviparin Approved, Investigational Phase 4 9041-08-1
20
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
21
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
22
Linaclotide Approved Phase 4 851199-59-2 16158208
23
Bemiparin Approved, Investigational Phase 4 91449-79-5
24
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
25
Phylloquinone Approved, Investigational Phase 4 84-80-0 5284607
26
Thrombin Approved, Investigational Phase 4
27
Misoprostol Approved Phase 4 59122-46-2 5282381
28
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
29
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
30
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
31
Bisacodyl Approved Phase 4 603-50-9 2391
32
Iron Approved Phase 4 7439-89-6 29936
33
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
34
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
35 Menaquinone Investigational Phase 4 1182-68-9
36 Antiprotozoal Agents Phase 4
37 Antiparasitic Agents Phase 4
38 Cathartics Phase 4
39 Laxatives Phase 4
40 Serotonin Receptor Agonists Phase 4
41
Histamine phosphate Phase 4 51-74-1 134614
42 Histamine H2 Antagonists Phase 4
43 Histamine Antagonists Phase 4
44 Platelet Aggregation Inhibitors Phase 4
45 Anticoagulants Phase 4
46 Hormones Phase 4
47 Antihypertensive Agents Phase 4
48 Hormone Antagonists Phase 4
49 Adrenergic beta-Antagonists Phase 4
50 Adrenergic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease Unknown status NCT04432233 Phase 4 Esomeprazole;Metronidazole;Levofloxacin
2 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
3 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
4 The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT00861640 Phase 4 Intravenous Omeprazole;Oral Rabeprazole
5 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
6 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
7 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
8 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
9 Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine Completed NCT00950339 Phase 4 omeprazole, 20mg twice daily;famotidine 40mg twice daily;pantoprazole 40mg once daily
10 Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
11 Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT02903017 Phase 4 Tranexamic acid 5%;Placebo
12 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding Completed NCT00838864 Phase 4 ceftrioxone
13 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
14 A Multi-centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding Completed NCT02349490 Phase 4
15 A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
16 Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial Completed NCT00978575 Phase 4 ferricarboxymaltose;Ferrosulfate;Placebo
17 Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy Completed NCT01169220 Phase 4 Go-Lytely;Go Lytely
18 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
19 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
20 The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding Completed NCT04358016 Phase 4 Terlipressin;Somatostatin
21 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
22 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
23 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
24 Randomized Controlled Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding Completed NCT01006824 Phase 4
25 Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Completed NCT02467621 Phase 4 Pantoprazole
26 Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease Completed NCT03667703 Phase 4 Famotidine;Placebo
27 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
28 Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study Completed NCT03980496 Phase 4 Omeprazole
29 Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding Completed NCT01806090 Phase 4 clopidogrel
30 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
31 Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study) Recruiting NCT03675672 Phase 4 Misoprostol Oral Tablet;Placebo Oral Tablet
32 The Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Acute Upper Gastrointestinal Bleeding: Double-blind Randomized Controlled Trial Recruiting NCT04771481 Phase 4 Metoclopramide;Normal Saline 10 mL Injection
33 Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study Recruiting NCT03624517 Phase 4 Octreotide
34 Examining the Effect of Ondansetron on Bowel Prep Success Recruiting NCT05439772 Phase 4 Ondansetron
35 A Comparison Between a High Dose PPI Intravenous Infusion and Oral Acid Pump Inhibitors After Endoscopic Haemostasis to Bleeding Peptic Ulcers Not yet recruiting NCT05582174 Phase 4 Vonoprazan;esomeprazole
36 Intravenous Ferric Carboxymaltose Versus Oral Ferrous Sulfate Replacement in Anaemia Due to Acute Nonvariceal Gastrointestinal Bleeding (FIERCE): Protocol of a Multicentre Randomised Controlled Trial Not yet recruiting NCT05060731 Phase 4 Oral iron supplementation;Intravenous iron supplementation
37 The Effect of Vonoprazan-based Dual Eradication Therapy vs PPI Treatment on Gastrointestinal Bleeding in ACS Patients With Hp Infection and Coronary Stents: an Open-label, Randomized, Controlled Trial Not yet recruiting NCT04728516 Phase 4 Vonoprazan-based dual eradication therapy for two weeks;amoxicillin;Pantoprazole
38 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
39 Oral vs Intravenous Proton Pump Inhibitor(PPI) in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Withdrawn NCT01123031 Phase 4 lansoprazole;esomeprazole
40 Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Unknown status NCT00553423 Phase 3 Lactulose;Placebo
41 A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias Unknown status NCT02384122 Phase 2, Phase 3 Octreotide
42 A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide Unknown status NCT00275184 Phase 3 Senna;Citramag powder;Metoclopramide
43 Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial. Unknown status NCT01716572 Phase 3 Erythromycin
44 Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery Unknown status NCT01351883 Phase 3
45 Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy Unknown status NCT01713101 Phase 3 Early intravenous tranexamic acid administration;placebo
46 Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding Unknown status NCT01628068 Phase 3
47 Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices Unknown status NCT03388125 Phase 3 Injection Sclerotherapy;N-butyl-2-cyanoacrylate
48 Emergency Capsule Endoscopy in Severe GI-bleeding Completed NCT01584869 Phase 2, Phase 3
49 Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill Completed NCT00045799 Phase 3 Omeprazole sodium bicarbonate immediate release PWD/FS;Cimetidine IV
50 Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65 Completed NCT01690585 Phase 3 Ferinject 1000 mg;Sodium chlorure 0,9 %

Search NIH Clinical Center for Active Peptic Ulcer Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
dihydroxyaluminum sodium carbonate
magaldrate
Magnesium Hydroxide
MILK OF MAGNESIA
Vasopressin (USP)
VASOPRESSIN TANNATE (IN OIL)

Genetic Tests for Active Peptic Ulcer Disease

Anatomical Context for Active Peptic Ulcer Disease

Organs/tissues related to Active Peptic Ulcer Disease:

MalaCards : Liver, Colon, Kidney, Lung, Heart, Small Intestine, Pancreas

Publications for Active Peptic Ulcer Disease

Articles related to Active Peptic Ulcer Disease:

(show top 50) (show all 3421)
# Title Authors PMID Year
1
Treatment and Bleeding Complications of Cancer-Associated Venous Thromboembolism: A Korean Population-Based Study. 62
35764307 2022
2
Socioeconomic factors and bleeding events in patients with incident atrial fibrillation: A Finnish nationwide cohort study. 62
36246774 2022
3
Clinical analysis of 99 children with Henoch-Schönlein purpura complicated with overt gastrointestinal bleeding. 62
35941339 2022
4
Long-term rebleeding rate and predictive factors of rebleeding after capsule endoscopy in patients with obscure GI bleeding. 62
35850171 2022
5
A novel bedside swallowed optical sensor for detection of upper GI bleeding. 62
36471712 2022
6
Evaluation and Treatment of GI Bleeding in a 51-Year-Old Man. 62
35718224 2022
7
Risk of Bleeding Among Individuals on Direct-Acting Oral Anticoagulants: An Academic Medical Center Cohort Study. 62
36084025 2022
8
Obscure Upper GI Bleeding After Liver Transplantation. 62
35863527 2022
9
Safety and efficacy of over-the-scope clips versus standard therapy for high-risk nonvariceal upper GI bleeding: systematic review and meta-analysis. 62
35803307 2022
10
In adults using oral anticoagulants, PPI use may be associated with lower risk for upper GI bleeding. 62
36315943 2022
11
INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding. 62
36444363 2022
12
A Glasgow-Blatchford Bleeding Score of >2 Is a Poor Predictor of Endoscopic Intervention in Nonvariceal Upper GI Bleeding. 62
36318950 2022
13
Patient and endoscopic characteristics and clinical outcomes in subjects with non-variceal GI bleeding referred for transarterial embolization: a single-center experience. 62
36031627 2022
14
Recurrent Gastrointestinal Bleed Due to Small Bowel Vascular Malformation in a Patient with Turner Syndrome Diagnosed with Surgically Assisted Push Enteroscopy. 62
36324242 2022
15
Evaluation of 30-day mortality in patients undergoing gastrointestinal endoscopy in a tertiary hospital: a 3-year retrospective survey. 62
36351757 2022
16
Safety and efficacy of direct oral anticoagulants in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study. 62
34931662 2022
17
Chronic Anti-Coagulation Therapy Reduced Mortality In Patients With High Cardiovascular Risk Early In COVID-19 Pandemic. 62
36415466 2022
18
Gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices: A comprehensive review. 62
36334280 2022
19
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. 62
35570250 2022
20
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. 62
36319907 2022
21
A 10 cm pedunculated duodenal Brunner gland hamartoma, case report and literature review. 62
36270207 2022
22
Meckel diverticulum in the pediatric population: Patient presentation and performance of imaging in prospective diagnosis. 62
35986976 2022
23
Characteristics Associated With Failure to Rescue After Open Abdominal Aortic Aneurysm Repair. 62
36459861 2022
24
Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. 62
36447806 2022
25
Sirolimus for management of GI bleeding in blue rubber bleb nevus syndrome: A case series. 62
36094280 2022
26
Nonsurgical periodontal treatment improved the type 2 diabetes mellitus status in smokers: A randomized controlled trial. 62
36375565 2022
27
Does coprescribing nonsteroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism? 62
35484847 2022
28
Risk factors of active upper gastrointestinal bleeding in patients with COVID-19 infection and the effectiveness of PPI prophylaxis. 62
36397007 2022
29
Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy. 62
36434811 2022
30
Scaling-up a pharmacist-led information technology intervention (PINCER) to reduce hazardous prescribing in general practices: Multiple interrupted time series study. 62
36383560 2022
31
Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. 62
35730192 2022
32
Prevalence of H. pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). 62
36198683 2022
33
Dyspepsia with alarm symptoms in patients aged less than 60 years: Is upper gastrointestinal endoscopy justified in Indian scenario? 62
36308702 2022
34
Motorized Spiral Enteroscopy versus Double Balloon Enteroscopy: A Case-Matched Study. 62
36228697 2022
35
Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patients. 62
35182354 2022
36
Outcomes of COVID-19 in Adult Males With Hemophilia A: A Propensity Score-Matched Analysis. 62
36439567 2022
37
Duodenal gastrointestinal stromal tumor: A case report. 62
36268398 2022
38
An unusual and life-threatening presentation of a large GIST. 62
36162355 2022
39
Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients - A cohort study. 62
36229879 2022
40
Hepatic arterial haemorrhage caused by duodenal ulcer. 62
36316056 2022
41
Recurrent bleeding duodenal and colonic ulcers due to post-transplant lymphoproliferative disorder. 62
36251246 2022
42
Gastric antral vascular ectasia (Watermelon stomach); an unusual cause of upper gastrointestinal bleeding in elderly: A case report. 62
36268406 2022
43
Early lactate clearance for predicting outcomes in patients with gastrointestinal bleeding. 62
36229587 2022
44
Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair. 62
35527697 2022
45
A Retrospective Analysis of Risk Factors for Mortality during Hemodialysis at a General Hospital that Treats Comprehensive Diseases. 62
36104191 2022
46
Pedunculated gastritis cystica profunda polyp presenting with upper GI bleeding and volcano-like surface alteration. 62
34162509 2022
47
Range and consistency of gastrointestinal outcomes reported in peritoneal dialysis trials: A systematic review. 62
36127835 2022
48
Are Proton Pump Inhibitors More Effective Than Histamine-2-Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients? A Systematic Review and Meta-Analysis of Cohort Studies. 62
34971320 2022
49
Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma. 62
35276075 2022
50
A jejunal gastrointestinal stromal tumor with massive gastrointestinal hemorrhage treated by emergency surgery: A case report. 62
36107510 2022

Variations for Active Peptic Ulcer Disease

Expression for Active Peptic Ulcer Disease

Search GEO for disease gene expression data for Active Peptic Ulcer Disease.

Pathways for Active Peptic Ulcer Disease

Pathways related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.19 VWF F7 F3 F2
2 11.49 VWF PTGS2 F3
3 10.73 VWF PTGS1 P2RY12 F2 CYP2C19
4 10.61 PTGS2 PTGS1 CRP
5 10.48 GPT F7
6 10.32 PTGS2 PTGS1
7 9.86 HRH2 ATP4A
8
Show member pathways
9.83 PTGS2 PTGS1 CYP2C19

GO Terms for Active Peptic Ulcer Disease

Cellular components related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 VWF SST KIT GPT F7 F3
2 serine-type peptidase complex GO:1905286 8.92 F7 F3

Biological processes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular oxidant detoxification GO:0098869 9.76 PTGS2 PTGS1 CYGB ALB
2 blood coagulation GO:0007596 9.61 VWF P2RY12 F7 F3 F2
3 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.56 F7 F3
4 hemostasis GO:0007599 9.17 VWF P2RY12 F7 F3 F2

Molecular functions related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.97 PTGS2 PTGS1 CYP2C19 CYGB
2 peroxidase activity GO:0004601 9.8 PTGS2 PTGS1 CYGB
3 oxygen binding GO:0019825 9.73 CYP2C19 CYGB ALB
4 P-type sodium:potassium-exchanging transporter activity GO:0005391 9.71 ATP4A ATP12A
5 P-type potassium:proton transporter activity GO:0008900 9.26 ATP4A ATP12A
6 P-type potassium transmembrane transporter activity GO:0008556 9.16 ATP4A ATP12A
7 prostaglandin-endoperoxide synthase activity GO:0004666 8.92 PTGS2 PTGS1

Sources for Active Peptic Ulcer Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....